View Ontology Report


Nateglinide is an anti-diabetic drug used as a blocker of the ATP-sensitive potassium channels (KATP) to promote insulin secretion and lower blood glucose levels in patients with type 2 diabetes mellitus (T2D). In response to elevated levels of circulating glucose; insulin is secreted from the pancreatic beta cells. This effect is counteracted by glucagon when the glucose levels are low - the two hormones act to maintain glucose homeostasis. The secretion of insulin from the isl

Pathway Diagram:

Ariadne Genomics Inc. uptaken nateglinide nateglinide and metabolites excretion nateglinide ---> uptaken nateglinide nateglinide metabolites ---> nateglinide and metabolites excretion CYP2C9 ---> nateglinide metabolites CYP3A4 ---> nateglinide metabolites nateglinide nateglinide metabolites CYP3A4 SLCO1B1 CYP2C9

Genes in Pathway:

show annotations for term's descendants       view all columns           Sort by:

Additional Elements in Pathway:

(includes Gene Groups, Small Molecules, Other Pathways..etc.)
Object TypePathway ObjectPathway Object Description
Small Moleculenateglinidenateglinide

Pathway Gene Annotations

References Associated with the nateglinide pharmacokinetics pathway:

Ontology Path Diagram:

paths to the root

Import into Pathway Studio: